Suppose the system can accommodate this proposal based on company submissions, PBAC advice and a ministerial policy decision. In that case, we should end the charade of a secret discussion about discount rates and comparator selection.
Is the system about to be seriously tested? Will it deliver? What will it deliver?
December 4, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News -
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL presses ahead with transformation as earnings slip and leadership changes
February 11, 2026 - - Latest News -
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 - - Latest News -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News

